CytoSure® high-quality, high-throughput arrays tailored for cytogenetics, oncology and rare disease genomics research, optimised to provide high sensitivity
Unlock insights down to single-exon level leveraging decades of hybridisation technology experience expertly employed in array development.
Expertly designed products, crafted with input from clinical scientists for robust calling of clinically relevant CNVs, SNVs and indels.
Unmatched customisation capabilities for cutting-edge results enabling you to include bespoke biomarker content to off-the-shelf arrays.
Every solution is supported to help your lab excel, backed by an expert team of responsive Field Application Specialists
Why are microarrays still relevant today?
High-quality arrays, standardised hybridisation protocols, accurate scanning technologies and robust computational methods have established DNA microarrays as powerful, mature and easy-to-use essential genomic tools. [1] Nowadays, DNA microarrays are recognised as first-tier tests for developmental delay (DD)/intellectual disability (ID), autism spectrum disorders, multiple congenital anomalies/dysmorphic features, cancers and the prenatal detection of clinically relevant copy number variations in foetuses. [2]
What is the CytoSure offering?
Arrays that maintain the superior standards and high throughput your clinical research demands.
The CytoSure® product portfolio includes DNA microarrays, genomic DNA labelling kits, and analysis software.
CytoSure is a range of products that have been developed with input from leaders in the fields of cytogenetics, cancer and rare disease research – which have been optimised to provide the most relevant content and sensitivity.
Our arrays are supported by our complimentary analytical software, CytoSure Interpret, which is a proprietary software package that has been designed to be adaptable and user-friendly.
How can CytoSure help you overcome daily challenges?
- Excellent CNV and LOH calling, down to the exon level
- High-resolution exon coverage of targeted genes for autism, epilepsy, cardiomyopathy, skeletal dysplasia, metabolic disorder and other rare diseases so that the mutation spectrum of these phenotypically and genetically heterogeneous diseases are efficiently interrogated
- Versatile cancer arrays with unique SNP probe technology so that any reference sample without restriction digest can be used
- Optimised genomic DNA labelling kits rapidly deliver high signal-to-noise ratios so that you can be confident in your data accuracy and reporting.
- Industry-leading, powerful and easy-to-use software package: CytoSure Interpret Software ensures that your oligo aCGH data translates into meaningful results, effortlessly.
- Continuous expert consultation by our medical scientific and application team so that you can be certain to achieve the best outcome from your array, every time
CytoSure® Custom arrays allow you to benefit from our extensive array design expertise to produce an array matching your precise specifications. These arrays are ideal if you want to know the precise coordinates of an aberration by analysing specific areas of the genome at high resolution.
Your unique requirements on content and format are fulfilled with maximum flexibility.
Our solutions
Downloads
More details from the manufacturer
Disclaimer
CytoSure®: for research use only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.
Manufacturer and Trademarks: CytoSure® (Oxford Gene Technology IP Limited)
References
[1] Trevino, V., Falciani, F., & Barrera-Saldaña, H. A. (2007). DNA microarrays: a powerful genomic tool for biomedical and clinical research. Molecular medicine (Cambridge, Mass.), 13(9-10), 527–541. https://doi.org/10.2119/2006-00107.Trevino
[2] Cheung, S. W., & Bi, W. (2018). Novel applications of array comparative genomic hybridization in molecular diagnostics. Expert review of molecular diagnostics, 18(6), 531–542. https://doi.org/10.1080/14737159.2018.1479253